Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs BlackRock TCP Capital Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while BlackRock TCP Capital Corp trades at $4.07 (market cap $335.61M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 2.9× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and BlackRock TCP Capital Corp for 89 Days on average.
| MRVI | TCPC | |
|---|---|---|
Market Cap | $972.90M | $335.61M |
Volume | 4,325,710 | 435,738 |
Sector | Health | Financials |
52-Week High | $9.00 | $6.20 |
52-Week Low | $2.83 | $3.13 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $1.08B | $1.09B |
Dividend Yield | — | 19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
TCPC trades at $3.98, showing no daily change. The stock exhibits a bullish technical signal, with moving averages supporting an uptrend. Recent Q2 2026 earnings beat expectations at $0.22 per share, and a $523 million portfolio sale has reduced leverage. However, fundamentals show negative revenue and net income trends, with a net loss of $88.93 million in 2025. The company maintains a dividend, with a $0.17 payment scheduled for September 2026.
The outlook is mixed. Positive technicals and strategic portfolio sales provide support, but persistent losses and a class action lawsuit pose significant risks. Analyst sentiment is cautious, with a majority recommending Hold. Investment potential hinges on the success of the strategic review and future profitability improvements amid ongoing financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
